Skip to main content

Advertisement

SpringerLink
Log in

Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor (HGF), and inhibitors, including endostatin, thrombospondin-1 (TSP-1), and angiostatin in the peripheral and bone marrow blood of MM patients at diagnosis and after high-dose chemotherapy. We have analyzed 96 patients with secretory MM. Serial measurements of angiogenesis factors/inhibitors were analyzed in the plasma by subgroups based on the best treatment response. Concentrations of angiogenic factors were determined in the peripheral blood and bone marrow plasma. There were significant decreases of VEGF and HGF levels and a significant increase in TSP-1 concentrations in the bone marrow plasma of patients who achieved complete or very good partial response in contrast to those who had partial or no response. VEGF and HGF levels decrease but those of TSP-1 increase after successful treatment for MM, indicating a reduction in the rate of angiogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adam Z, Hajek R, Mayer J et al (1999) Multiple myeloma and other monoclonal gammapathies. Masaryk university, Brno 325

    Google Scholar 

  2. Vacca A, Ribatti D (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87(3):503–508

    Article  CAS  PubMed  Google Scholar 

  3. Vacca A, Ribatti D (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20(2):193–199

    Article  CAS  PubMed  Google Scholar 

  4. Rajkumar SV, Leong T, Roche PC et al (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (United States) 6(8):3111–3116

    CAS  Google Scholar 

  5. Orpana A (2002 Feb) Angiogenic and lymphangiogenic molecules in hematological malignancies. Leuk Lymphoma 43(2):219–224

    Article  CAS  PubMed  Google Scholar 

  6. Neben K, Moehler T, Egerer G (2001) High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 7(9):2675–2681

    CAS  PubMed  Google Scholar 

  7. Ščudla V et al (2006) Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma. Vnitr Lek 52(3):232–240 Czech

    PubMed  Google Scholar 

  8. Iwasaki T (2002) Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte Folkman, J.: role of angiogenesis in tumor growth and metastasis. Semin Oncol 20:15–18

    Google Scholar 

  9. Sezer O, Jakob C, Eucker J et al (2001) Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 66(2):83–88

    Article  CAS  PubMed  Google Scholar 

  10. Sato N et al (2002 Apr) Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity. Jpn J Cancer Res 93(4):459–466

    CAS  PubMed  Google Scholar 

  11. Wrobel T, Mazur G, Surowiak P et al (2003) Increased expression of vascular endothelial growth factor in bone marrow of multiple myeloma patients. Eur J Intern Med 14(2):98–100

    Article  CAS  PubMed  Google Scholar 

  12. Standal T, Abildgaard N, Fagerli U, et al HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109:3024-3030

  13. Voest E, D’Amore P (2001) Tumor angiogenesis and microcirculation. Marcel Dekker AG, New York, p 623s

    Google Scholar 

  14. Urbanska-Rys J (2003) High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Mediat Inflamm 12(4):229–235

    Article  CAS  Google Scholar 

  15. Du W et al (2006) NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells in vivo; molecular targeting of angiogenic growth factor. Blood 19; (Epub ahead of print)

  16. Attal M, Harousseau JL, Stoppa AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335(2):91–97

    Article  CAS  PubMed  Google Scholar 

  17. Hajek R, Spicka I, Scudla V et al (2007) Consolidation therapy based on conventional chemotherapy and corticoids do not provide therapeutic advantage for newly diagnosed patients after autologous transplantation. Blood 110:531

    Google Scholar 

  18. Durie BG, Harousseau JL, Miguel J et al (2006) International myeloma working group: international uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473

    Article  CAS  PubMed  Google Scholar 

  19. Alexandrakis MG, Passam FH, Sfiridaki A et al (2003) Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol (United States) 72(4):229–233

    Article  CAS  Google Scholar 

  20. Smolej L, Andrys C, Belada D, Pour L, Zak P, Krejsek J, Novosad J, Hrudkova M, Siroky O, Voglova J, Maly J (2006) Plasma soluble endoglin (sCD105) concentrations in patients with lymphoid malignancies—a pilot study. Br J Haem 133(Suppl.1):104 abstract 269

    Google Scholar 

  21. Mileshkin L, Honemann D, Gambell P et al (2007) Haematologica 92:1075–1082

    Article  CAS  PubMed  Google Scholar 

  22. Cibeira MT, Rozman M, Segarra M et al (2008 Mar) Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 41(3):244–253

    Article  CAS  PubMed  Google Scholar 

  23. Pour L, Svachova H, Adam Z, et al (in press) Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma

  24. Vacca A, Ria R, Ribatti D et al (2003) A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (Italy) 88(2):176–185

    CAS  Google Scholar 

  25. Holt RU (2005) Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 90(4):479–488

    CAS  PubMed  Google Scholar 

  26. Kazerounian K, Yee O, Lawler J (2008) Thrombospondins: from structure to therapeutics. Cell Mol Life Sci 65(5):700–712

    Article  CAS  PubMed  Google Scholar 

  27. Oganesian A, Armstrong LC, Migliorini MM (2008) Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19(2):563–571

    Article  CAS  PubMed  Google Scholar 

  28. Kalas W, Rak J (2005) Oncogenes and Angiogenesis: downregulation of trombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 65(19):8878–8886

    Article  CAS  PubMed  Google Scholar 

  29. Pour L, Kovarova L, Büchler T, Penka M, Vorlicek J, Hajek R (2009) Evaluation of hepatocyte growth factor and endostatin in the bone marrow of patients with multiple myeloma and the effect of peripheral blood admixture. Scripta medica 82:123–126

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departement of Internal Medicine-Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic

    Ludek Pour, Zdenek Adam, Miroslav Penka, Jiri Vorlicek & Roman Hajek

  2. Czech Myeloma Group, University Research Centre, Brno, Czech Republic

    Ludek Pour, Hana Svachova, Zdenek Adam, Martina Almasi, Lucie Kovarova, Pavel Nemec & Miroslav Penka

  3. Institute of Biostatistics and Analyses at the Faculty of Medicine, Faculty of Science of the Masaryk University, Brno, Czech Republic

    Lucie Buresova & Miroslav Penka

  4. Departement of Oncology, 1st Faculty of Medicine and Thomayer University Hospital, Prague, Czech Republic

    Tomas Buchler & Miroslav Penka

  5. Departement of Clinical Hematology, University Hospital Brno, Brno, Czech Republic

    Miroslav Penka

  6. University Hospital Brno, Jihlavská, 20 625 00, Brno, Czech Republic

    Ludek Pour

Authors
  1. Ludek Pour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hana Svachova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zdenek Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martina Almasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lucie Buresova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomas Buchler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lucie Kovarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pavel Nemec
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Miroslav Penka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jiri Vorlicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Roman Hajek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ludek Pour.

Additional information

This research was supported by grants MSMT LC 06027, MSM 0021622434, and IGA MZCR NR/9225

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pour, L., Svachova, H., Adam, Z. et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 89, 385–389 (2010). https://doi.org/10.1007/s00277-009-0834-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0834-3

Keywords

Search

Navigation